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PERSONALIZED MEDICINE AND POLICY TO BE 
IMPLEMENTED: TH E EUROPEAN CHEMIST POINT OF VIEW
Personalized medicine may represent a dramatic change 
of paradigm in the medium-term future. For a chemist, 
personalized medicine means the definition and under-
standing of any disease on molecular level for each individ-
ual or group of individuals (personalized diagnosis) ideally 
leading to the design of a drug that efficiently counteracts 
or prevents any molecular dysfunction, ie, a personalized 
drug without side effects.
The interdisciplinary research required for personalized 
medicine should overcome a myriad of obstacles not the 
least being to find specific biomarkers and targets for each 
individual or group of individuals suffering from a given 
disease. Chemists enter then into action and will model/
design drugs and drug delivery pathways for a personal-
ized therapy. They will either tap into the numerous drugs 
candidates, which were abandoned at some stage of clini-
cal trials, or synthesize new drugs, mainly those “small mol-
ecules” mimicking the activity of natural products.
This view has obvious economic, ethical, and social impli-
cations, beyond scientific challenges. All stakeholders will 
have to take them into account. Policy makers will have to 
examine all disciplines of regulatory science among which 
the thorny economics (cost-benefit analysis of specific re-
search and development projects) are of paramount im-
portance and critical to the development of personalized 
medicine.
Thus competing/conflicting interests of “drugs producers” 
and “drugs payers” need to be reconciled. It requires resolv-
ing intricate issues, which include how to advance trans-
lational medical science, how to “reward” new findings 
on old drugs, and how to deal with intellectual property 
rights when new products and approaches are incorporat-
ed into clinical practice as the results of an interdisciplinary 
endeavor, very often not stemming from a single country. 
As a corollary, there is as well European Patent question, 
which looks a bit of a holy grail, and ultimately the most 
important one: is it cost-effective for the very different 
health care systems to uptake personalized medicine?
From the chemist’s point of view, these are several of the 
key policy issues needing to be addressed and answered 
to help personalized medicine have a bright future, that 
is for physician/clinician to prescribe the right drug at the 
right dose at the right time for every person.
MEDICINAL CHEMISTRY AND PERSONALIZED MEDICINE 
AS THEY ARE AND AS THEY MIGHT BE
Medicinal chemistry comprises several scientific disci-
plines: organic chemistry, bioorganic chemistry, physical 
organic chemistry, biochemistry, pharmacology, toxicol-
ogy, molecular biology, analytical chemistry, engineering, 
genetics, etc. Nowadays, this complex approach is signifi-
cantly developing and allows gaining a novel level – per-
sonalized medicine. It means: choice of a drug and its 
use regime should fit every individual specifically, so 
efficacy of medicinal treatment would improve sig-
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nificantly. Such a progress is possible thanks to a novel ap-
proach in many branches, eg, nowadays polypharmacol-
ogy is developing fast. It means that pleiotropic properties 
of compounds, which were treated negatively for a long 
time, considered in many cases as side effects, are recon-
sidered gradually as desirable bioactivities. Therefore, ex-
clusively selective compounds that have been a quest for 
decades are not any more considered as golden standards. 
On the contrary, many well known, powerful, and success-
ful drugs turned out to be “dirty.” They are beneficial since 
due to their pleiotropic properties they regulate several 
signaling pathways, which was not realized when they 
were introduced as drugs with a single activity principle.
The European Cooperation in Science and Technology 
(COST) conference “Personalised Medicine: Better Health-
care for the Future – A Rational Approach Focusing on 
Bioinformatics, Medicinal Chemistry and Medicine” was a 
significant event to establish new principles for the medi-
cine of the future (1). It is a milestone in the fast develop-
ment of medicinal chemistry and drug development. This 
strategic COST conference fits the general mission of the 
COST goals very well: to pick up novel emerging features 
and principles in science, to support them, and to bring 
attention of society on the most important novelties. The 
conference demonstrated the importance of collabora-
tion of many specialists to create innovative products for 
health care, and food, vitamins, nutritional supplements, 
as well as high tech materials (2). A series of 18 interviews 
made on COST Strategic Conference deliver the take-
home message from different stakeholders (policy mak-
ers, patient associations, scientists, and clinicians) (http://
www.youtube.com/playlist?list=PL08CF13F5A0482A2B&
feature=plcp). Prof. Alain van Gool (coordinator Personal 
medicine, Netherlands Organization for Applied Scientif-
ic Research) turned attention to the relevance of system 
biology: to monitor the effect of interventions on the hu-
man system as a whole and timely adjust when needed 
(3). When organism turns from healthy state to disease (eg, 
diabetes, its complications, including nephropathy, brain 
disorders, cardiovascular events, etc), gradual disturbances 
of multiple equilibriums occur. Therefore, several special-
ists should participate in studies of medicinal chemistry 
and personalized medicine. The potential for multi-target 
drugs is significant; it coincides with evolvement of novel 
drug discovery paradigm of designed polypharmacology. 
Such innovative task will need to involve coordinated col-
laboration of many specialists. Optimizing preconditions 
for that is “a must” both for scientists and for policy mak-
ers, who should create jointly functional and trusty 
networking links between academia and industry, both on 
regional and on global level supporting research and de-
velopment (4).
PERSONALIZED BIO-INTERDISCIPLINARITY
The past decade in science may be considered as a period 
of adjustment to the dynamic processes of globalization 
associated with overall crises; moral, political, and finan-
cial. Similar processes happened several times in the 20th 
century, but the question of optimal strategic approach to 
solve the crisis has never before been science policy-de-
pendent as nowadays. Therefore, again, as in the seventies, 
the time is right for science to “functionalize policy” by pro-
viding and influencing policy makers and decision makers. 
The COST, being born in the period of global turbulences 
forty years ago, might be the optimal system to fulfill such 
a demanding goal. As it was successful in overcoming the 
“iron curtain,” COST could be successful in providing inter-
disciplinarity in science for a better, healthy life, which is of 
highest importance for the modern, aging society.
It is important to underline the fact that chemistry is a ma-
jor industry in Europe, which is a global leader in chemis-
try and related technologies. However, global markets and 
globalized sciences do not make optimal preconditions to 
develop further bio-interdisciplinarity for the healthy life 
in Europe. Although globalization implies integration pro-
cesses, European diversities still represent obstacles for the 
set up of the European Research Area, while global econo-
mies do not support defining pan-European research and 
development strategy. The vision of Europe 2020, with a 
flagship initiative of Innovation Union, does not appear re-
alistic without the fast and affordable European patenting 
system that could allow the common principle of “first file 
then publish” to be daily practice for researchers in Europe. 
Europe has to be an example of wisely using interdisciplin-
arity in science for the better world of stable research and 
development and healthy life.
The strategic COST conference in Larnaca clearly pointed 
to the need of bringing policy makers together with the 
prominent scientists oriented to the interdisciplinarity. 
Modern concepts of integrative medicine are based on in-
terdisciplinarity of life sciences. In the center of this stands 
a healthy modern man, considered as a valuable member 
of society giving optimal personal contribution to all. How-
ever, the average age of modern European is above 40, 
now with expected life expectancy around 80. Thus, the 
average healthy Europeans in 2012 already develop chron-
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ic stress- and age-associated disorders. In 2030-2035, they 
will be chronically ill and will stay so for 15-20 years at least. 
To make the perspective even darker we have to admit 
that we still do not know how to prevent the major chron-
ic diseases of the modern man, how to diagnose them in 
time, and how to treat them optimally.
As many times before, chemistry and molecular technolo-
gies are at the front of changes combining green chemis-
try and mimetic chemistry with medicinal chemistry and 
nanotechnologies. The respective COST Domain is thus 
flooded with emerging interdisciplinarity in many Ac-
tions like in epigenetics and theragnostics, linking them 
with major tasks of modern biomedicine such as cancer 
stem cells and neurodegenerative disorders. Supporting 
such interdisciplinarity, COST provides strong pillar for the 
brighter future in personalized medicine and healthy life. 
Policy makers should support these trends fast and strong-
ly so that we could jointly define and introduce the really 
healthy life to all.
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